Having trouble accessing articles? Reset your cache.

Taspoglutide: Additional Phase III data

Roche discontinued dosing of patients in the 8 Phase III trials of its T-emerge program of taspoglutide to treat Type II diabetes after 52-week data from

Read the full 268 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE